Unknown

Dataset Information

0

Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors.


ABSTRACT: Effective cancer therapies simultaneously restrict tumor cell growth and improve anti-tumor immune responses. Targeting redox-dependent protein folding enzymes within the endoplasmic reticulum (ER) is an alternative approach to activation of the unfolded protein response (UPR) and a novel therapeutic platform to induce malignant cell death. E64FC26 is a recently identified protein disulfide isomerase (PDI) inhibitor that activates the UPR, oxidative stress, and apoptosis in tumor cells, but not normal cell types. Given that targeting cellular redox homeostasis is a strategy to augment T cell tumor control, we tested the effect of E64FC26 on healthy and oncogenic T cells. In stark contrast to the pro-UPR and pro-death effects we observed in malignant T cells, we found that E64FC26 improved viability and limited the UPR in healthy T cells. E64FC26 treatment also diminished oxidative stress and decreased global PDI expression in normal T cells. Oxidative stress and cell death are limited in memory T cells and we found that PDI inhibition promoted memory traits and reshaped T cell metabolism. Using adoptive transfer of tumor antigen-specific CD8 T cells, we demonstrate that T cells activated and expanded in the presence of E64FC26 control tumor growth better than vehicle-matched controls. Our data indicate that PDI inhibitors are a new class of drug that may dually inhibit tumor cell growth and improve T cell tumor control.

SUBMITTER: Hurst KE 

PROVIDER: S-EPMC6953024 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors.

Hurst Katie E KE   Lawrence Kiley A KA   Reyes Angeles Lety L   Ye Zhiwei Z   Zhang Jie J   Townsend Danyelle M DM   Dolloff Nathan N   Thaxton Jessica E JE  

Cells 20191126 12


Effective cancer therapies simultaneously restrict tumor cell growth and improve anti-tumor immune responses. Targeting redox-dependent protein folding enzymes within the endoplasmic reticulum (ER) is an alternative approach to activation of the unfolded protein response (UPR) and a novel therapeutic platform to induce malignant cell death. E64FC26 is a recently identified protein disulfide isomerase (PDI) inhibitor that activates the UPR, oxidative stress, and apoptosis in tumor cells, but not  ...[more]

Similar Datasets

| S-EPMC2673250 | biostudies-literature
| S-EPMC4019026 | biostudies-literature
| S-EPMC1087927 | biostudies-literature
| S-EPMC4597791 | biostudies-literature
| S-EPMC5655420 | biostudies-literature
| S-EPMC3369880 | biostudies-literature
| S-EPMC6443025 | biostudies-literature
| S-EPMC11342103 | biostudies-literature
| S-EPMC9847472 | biostudies-literature
| S-EPMC6875354 | biostudies-literature